Status:
COMPLETED
Nocturnal TLA for Severe Allergic Asthma After Withdrawal of Omalizumab Therapy
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Severe Allergic Asthma
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
This is a randomized, controlled study with a 48-week treatment phase to determine the clinical efficacy of temperature controlled laminar flow device (TLA, Airsonett™) in the patients with severe all...
Detailed Description
This is a randomized, controlled study with a 48-week treatment phase to determine the clinical efficacy of temperature controlled laminar flow device (TLA, Airsonett™) in the patients with severe all...
Eligibility Criteria
Inclusion
- Willing to sign a written consent form
- Male and female subjects were diagnosed severe allergic asthma and received omalizumab as add-on therapy for more 4 than months and had stable asthma control.
- Men and women over the age of 20 and less than 80 year-old
- Accept application of TLA or not after withdrawal of omalizumab therapy
- Positive reaction of specific IgE (Phadiatop) for one or more than on indoor allergens.
Exclusion
- Having an exacerbation within 4 weeks before entry the study
- Using immunosuppressants within 3 months of the first visit
- Having recent upper airway infection or systemic corticosteroid usage within 4 weeks
- Bronchiectasis
- Active pulmonary tuberculsis
- COPD
- Cystic fibrosis
Key Trial Info
Start Date :
January 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2020
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03480815
Start Date
January 20 2017
End Date
June 30 2020
Last Update
June 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital
Taoyuan District, Taiwan